Natco Pharma today announced submission of Abbreviated New Drug Application (ANDA) with USFDA  for Risdiplam for Oral Solution. NATCO believes it is amongst one of the first two companies to have filed a substantially-complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of shared marketing exclusivity at the time of potential launch of the generic product under certain circumstances. NATCO has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. EVRYSDI� has recorded sales of USD 571 million in the US market for the year 2023. Risdiplam for Oral Solution is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.Powered by Capital Market - Live News

Net profit of Natco Pharma rose 83.55% to Rs 677.30 crore in the quarter ended September 2024 as against Rs 369.00 crore during the previous quarter ended September 2023. Sales rose 32.94% to Rs 1371.10 crore in the quarter ended September 2024 as against Rs 1031.40 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1371.101031.40 33 OPM %58.6644.41 - PBDT864.00483.20 79 PBT818.20439.60 86 NP677.30369.00 84 Powered by Capital Market - Live News

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 November 2024, inter alia, have recommended the second interim dividend of Rs 1.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Natco Pharma has fixed 25 November 2024 as record date for 2nd interim dividend of Rs 1.50 per share for FY 2024-25. The dividend will be paid on 02 December 2024. Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live News